Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.

Experimental and clinical psychopharmacology - 1 Apr 2009

Ray Lara A, Miranda Robert, MacKillop James, McGeary John, Tidey Jennifer W, Rohsenow Damaris J, Gwaltney Chad, Swift Robert W, Monti Peter M

Abstract excerpt

Topiramate, an anticonvulsant medication, is an efficacious treatment for alcohol dependence. To date, little is known about genetic moderators of side effects from topiramate. The objective of this study was to examine 3 single nucleotide polymorphisms (SNPs) of the glutamate receptor GluR5 gene (GRIK1) as predictors of topiramate-induced side effects in the context of a laboratory study of topiramate. Heavy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Fructose

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Receptors, Kainic Acid

Share to Severity of Illness Index

Source

Open in PubMed Open full text

Identifiers

PMID: 19331489
DOI: 10.1037/a0015700
PMCID: PMC3682424

Genes

GRIK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.PMID 19331489Read ↗

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures.Semantic proximity Read ↗

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.Semantic proximity Read ↗

Posttreatment effects of topiramate treatment for heavy drinking.Semantic proximity Read ↗

Molecular correlates of topiramate and <i>GRIK1</i> rs2832407 genotype in pluripotent stem cell-derived neural culturesSemantic proximity Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence.Semantic proximity Read ↗

GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.